The Russian Health Ministry had sanctioned the trial for the coronavirus vaccine candidate on June 16. The first group of volunteers would be discharged on July 15 and the second group on July 20.
Vadim Tarasov, the Director of the Institute for Translational Medicine and Biotechnology, told Sputnik that the university has completed the trial of the vaccine developed by the Gamaleya Institute, an epidemiology research centre in Moscow.The first group of 18 volunteers received the vaccine on June 18 while the second group of 20 volunteers on June 23 at the Practical Research Centre for Interventional Cardiovasology, Sechenov University had said earlier this month.
Tarasov said the first group of volunteers would be discharged on July 15 and the second group on July 20.
Participants are deliberately exposed to the infection (in this case it is SARS-CoV-2 virus), in order to study the disease and test the vaccines. For the human challenge trial the exact virus strain that is used to infect the participant and dosage or how much of the virus the volunteers need to be exposed to needs to be determined and approved by the regulatory authorities.This method is not new and has been used for seasonal flu.